ANNOUNCEMENT NO. 299 4 February 2026 Interim report for the first half of 2025/26 Organic growth despite challenges in the North American market Martin Helbo Behrens, CEO: In the first half of 2025/26, our revenue was up 3% measured in local currencies, while in Danish kroner it was down to DKK 249.0 million, a year-on-year decrease of 1%. Despite this, EBITDA and the EBITDA margin showed a slight increase. Revenue was affected by a sharp slowdown in US demand, as many of our customers in the USA were sev ...

Core Viewpoint - ChemoMetec has upgraded its revenue and EBITDA guidance for the financial year 2025/26 due to increased interest in its technology, particularly the XcytoMatic platform [1][2]. Financial Performance - Revenue for the financial year 2025/26 is now expected to be in the range of DKK 565-580 million, an increase from the previously announced DKK 545-565 million [2]. - EBITDA is anticipated to be between DKK 320-335 million, up from the earlier forecast of DKK 295-315 million [2]. Company Overview - ChemoMetec develops, manufactures, and markets instruments for cell counting and various other measurements, targeting the pharmaceutical, biotech, and agricultural industries globally [3]. - The company serves some of the world's leading pharmaceutical companies [3]. - ChemoMetec was founded in 1997 and is listed on Nasdaq OMX Copenhagen [4].